Cabergoline monotherapy in the long-term treatment of Cushing's disease.

  title={Cabergoline monotherapy in the long-term treatment of Cushing's disease.},
  author={Ariane Godbout and Marcos Paulo Manavela and Karina Danilowicz and Hugues Beauregard and Oscar Domingo Bruno and Andr{\'e} Lacroix},
  journal={European journal of endocrinology},
  volume={163 5},
BACKGROUND Cabergoline is a long-acting dopamine receptor agonist used to treat prolactinomas. Identification of D(2) receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH-secreting tumors, and recently Cushing's disease (CD). OBJECTIVE To evaluate the long-term efficacy of cabergoline monotherapy in patients with CD. METHODS Retrospective analysis of non-randomized clinical therapy with cabergoline in 30 patients… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 69 extracted citations


Publications referenced by this paper.
Showing 1-10 of 42 references

European Journal of Endocrinology

  • A Klibanski, A Lacroix, +9 authors M. Boscaro
  • 2010

Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine Cushing’s disease

  • C De Bruin, JM Hanson, +5 authors LJ. Hofland
  • Endocrinology
  • 2008

Long - term therapy with cabergoline in Cushing ’ s disease

  • L Vilar, LA Naves, +9 authors V Canadas
  • 2008

Similar Papers

Loading similar papers…